ReviewMolecular cancer2013
Tumor glycolysis as a target for cancer therapy: progress and prospects.
Review in Molecular cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 785 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
785 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,443 citations in OpenAlex.
- Human blood metabolites and gastric cancer: a Mendelian randomization analysis.BMC gastroenterology · 2024Pooled it
- Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progressionCancer biology & therapy · 2026Article
- Significance of GSH and HRedox report : communications in free radical research · 2026Review
- Theranostic Potential of an NAD(P)H-Activatable Fluorophore: Assessing Cancer Aggressiveness and Triggering Apoptosis.Angewandte Chemie (International ed. in English) · 2026Article
- Inhibition of vasculogenic mimicry by 22-benzyloxydaphlongaminone via glycolysis suppression.The Journal of antibiotics · 2026Article
- Mitochondrial Metabolic Reprogramming in Glioma: Mechanisms of Tumorigenesis and Implications for Clinical Therapy.CNS neuroscience & therapeutics · 2026Review
- Review
- LncRNA PCAT7 drives tumorigenesis and glycolytic reprogramming in breast cancer via the ceRNA-mediated miR-204-5p/RUNX2 axis.Cancer gene therapy · 2026Article
- Integrative Transcriptomic Analysis and Functional Validation Implicate GPT2 in Glycolytic Regulation in Polycystic Ovary Syndrome.Food science & nutrition · 2026Article
- Multi-omics-driven precision medicine.iMeta · 2026Review
- DDX3x Regulates NINJ1 Transcription via Histone Lactylation in Sepsis Associated-Acute Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Covalent inhibition of New Delhi metallo-β-lactamases NDM-1 and NDM-5 by 3-bromopyruvate.JAC-antimicrobial resistance · 2026Article
- MiR-138-5p Suppresses Glucose Metabolism to Inhibit the Progression of Nasopharyngeal Carcinoma by Targeting the CENPN/PI3K/Akt/mTOR Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Metabolic-epigenetic reprogrammingActa pharmaceutica Sinica. B · 2026Article
- An externally validated lactylation-associated prognostic signature for overall survival prediction in lung adenocarcinoma identifiesTranslational cancer research · 2026Article
- Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma.Cell death & disease · 2026Article
- [Methyltransferase-like protein 7B promotes glycolysis and malignant progression in papillary thyroid carcinoma cells via the USP28/HIF-1α axis].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Metaproteomic profiling reveals viral proteins and associated host proteomic alterations in glioblastoma.Scientific reports · 2026Article
- Lactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- On why cancer cells require a great amount of glucose.Quantitative biology (Beijing, China) · 2026Article
725 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered energy metabolism is a biochemical fingerprint of cancer cells that represents one of the "hallmarks of cancer". This metabolic phenotype is characterized by preferential dependence on glycolysis (the process of conversion of glucose into pyruvate followed by lactate production) for energy production in an oxygen-independent manner. Although glycolysis is less efficient than oxidative phosphorylation in the net yield of adenosine triphosphate (ATP), cancer cells adapt to this mathematical disadvantage by increased glucose up-take, which in turn facilitates a higher rate of glycolysis. Apart from providing cellular energy, the metabolic intermediates of glycolysis also play a pivotal role in macromolecular biosynthesis, thus conferring selective advantage to cancer cells under diminished nutrient supply. Accumulating data also indicate that intracellular ATP is a critical determinant of chemoresistance. Under hypoxic conditions where glycolysis remains the predominant energy producing pathway sensitizing cancer cells would require intracellular depletion of ATP by inhibition of glycolysis. Together, the oncogenic regulation of glycolysis and multifaceted roles of glycolytic components underscore the biological significance of tumor glycolysis. Thus targeting glycolysis remains attractive for therapeutic intervention. Several preclinical investigations have indeed demonstrated the effectiveness of this therapeutic approach thereby supporting its scientific rationale. Recent reviews have provided a wealth of information on the biochemical targets of glycolysis and their inhibitors. The objective of this review is to present the most recent research on the cancer-specific role of glycolytic enzymes including their non-glycolytic functions in order to explore the potential for therapeutic opportunities. Further, we discuss the translational potential of emerging drug candidates in light of technical advances in treatment modalities such as image-guided targeted delivery of cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.